The TGA's GCP Inspection Program now recognizes ISO 14155:2026 with a 12-month transition period, requiring implementation plans and revised safety reporting practices for compliance.
This update ensures that safety reporting and vigilance methodologies match the latest international standards, enhancing participant safety and data integrity in clinical trials.
Sponsors and investigators must develop an implementation plan for the ISO 14155:2026 standard and maintain records for review during TGA inspections, ensuring alignment with updated safety monitoring obligations.
Regulatory Intelligence Lead
Review before 2026-03-31.
Recognition of ISO 14155:2026; establishes a 12-month transition period; requires sites to develop an implementation plan and maintain records of the review of the new standard for TGA inspection purposes; launch of new GCP eLearning modules.
Sponsors and investigators conducting medical device clinical investigations must update their safety reporting and vigilance procedures to align with ISO 14155:2026. Compliance with the new standard's safety monitoring obligations will be evaluated during TGA GCP inspections.
Sponsors and investigators must develop an implementation plan for the ISO 14155:2026 standard and maintain records for review during TGA inspections, ensuring alignment with updated safety monitoring obligations.
The Therapeutic Goods Administration (TGA) has updated its Good Clinical Practice (GCP) Inspection Program to recognize ISO 14155:2026 as the current standard for clinical investigations of medical devices. A 12-month transition period is established, beginning March 31, 2026, requiring sites to maintain implementation plans and records for TGA inspections. This change mandates that sponsors and investigators revise their safety reporting and vigilance procedures to align with the new standard.
What changed: The TGA's GCP Inspection Program now recognizes ISO 14155:2026 with a 12-month transition period, requiring implementation plans and revised safety reporting practices for compliance.
Why it matters: This update ensures that safety reporting and vigilance methodologies match the latest international standards, enhancing participant safety and data integrity in clinical trials.
Practical implication: Sponsors and investigators must develop an implementation plan for the ISO 14155:2026 standard and maintain records for review during TGA inspections, ensuring alignment with updated safety monitoring obligations.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
